A woeful tale of ex-Pfizer chief Jeff Kindler

Ex-CEO Jeff Kindler's quick departure from Pfizer's helm may have been dramatic, but it was nothing compared to the ups and downs of his tenure. According to Fortune's well-worth-reading saga, Kindler was a second-guessing, temper-losing, midnight-calling micro-manager. No wonder current chief Ian Read threatened to leave. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.